Surrogate and intermediate endpoints in randomized trials: What's the goal?

14Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

Establishing trial-level surrogacy of an intermediate endpoint for predicting survival benefit in future trials is extremely challenging because of the extrapolations required, but there are other useful drug development and patient management applications of intermediate endpoints.

Cite

CITATION STYLE

APA

Korn, E. L., & Freidlin, B. (2018). Surrogate and intermediate endpoints in randomized trials: What’s the goal? Clinical Cancer Research, 24(10), 2239–2240. https://doi.org/10.1158/1078-0432.CCR-18-0183

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free